Deracoxib

Deracoxib is a non-steroidal anti-inflammatory drug (NSAID) and selective inhibitor of COX-2 (IC₅₀s = 0.63 and 23 μM for COX-2 and COX-1, respectively).¹ In vivo, deracoxib (0.3-10 mg/kg) increases weight bearing and decreases lameness and joint effusion in a canine model of urate crystal-induced intraarticular synovitis.² Deracoxib induces less lesion formation in the gastric mucosa of healthy canines than aspirin (Item No. 70260) when administered at a dose of 1.5 mg/kg.³ Formulations containing deracoxib have been used in the treatment of pain associated with canine osteoarthritis.

WARNING This product is not for human or veterinary use.

1. Li, J., DeMello, K.M.L., Cheng, H., et al. Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine. Bioorg. Med. Chem. Lett. 14(1), 95-98 (2004).

2. Millis, D.L., Weigel, J.P., Moyers, T., et al. Effect of deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. Vet. Ther. 3(4), 453-464 (2002).

3. Sennello, K.A., and Leib, M.S. Effects of deracoxib or buffered aspirin on the gastric mucosa of healthy dogs. J. Vet. Intern. Med. 20(6), 1291-1296 (2006).